Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 1, 2012, Pages 109-121

  Alfarone, Andrea ^a   Panebianco, Valeria ^a   Schillaci, Orazio ^b   Salciccia, Stefano ^a   Cattarino, Susanna ^a   Mariotti, Gianna ^a   Gentilucci, Alessandro ^a   Von Heland, Magnus ^a   Passariello, Roberto ^a   Gentile, Vincenzo ^a   Sciarra, Alessandro ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Imaging; Local recurrence; Prostate neoplasm; Radical prostatectomy

Indexed keywords

ACETIC ACID C 11; CARBON 11; CHOLINE; CHOLINE F 18; CITRIC ACID; CREATINE; FLUORODEOXYGLUCOSE F 18; METHIONINE C 11; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

CANCER RECURRENCE; CELL METABOLISM; COCHRANE LIBRARY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MALE; MEDLINE; MULTIPARAMETRIC NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTIVE VALUE; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TUMOR VOLUME;

HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS;

EID: 84866512385     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.01.006     Document Type: Review

References (48)

1. Bill-Axelson A., Holmberg L., Filén F., et al. Scandinavian Prostate Cancer Group Study Number 4. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008, 100(August (16)):1144-1154. [Epub 2008 August 11].
2. Bianco F.J., Scardino P.T., Eastham J.A. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (" trifecta"). Urology 2005, 66(November (5 Suppl.)):83-94.
3. Freedland S.J., Presti J.C., Amling C.L., et al. SEARCH Database Study Group. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology 2003, 61(April (4)):736-741.
4. Han M., Partin A.W., Zahurak M., Piantadosi S., Epstein J.I., Walsh P.C. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003, 169(February (2)):517-523.
5. Grossfeld G.D., Stier D.M., Flanders S.C., et al. Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database. J Urol 1998, 160(October (4)):1398-1404.
6. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Partin A.W. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 2006, 176(October (4 Pt 1)):1404-1408.
7. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281(May (17)):1591-1597.
8. Moul J.W. Prostate specific antigen only progression of prostate cancer. J Urol 2000, 163(June (6)):1632-1642.
9. Amling C.L., Bergstralh E.J., Blute M.L., Slezak J.M., Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol 2001, 165(April (4)):1146-1151.
10. Stephenson A.J., Kattan M.W., Eastham J.A., et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006, 24(August (24)):3973-3978.
11. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65(July (4)):965-974.
12. Marks R.A., Koch M.O., Lopez-Beltran A., Montironi R., Juliar B.E., Cheng L. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. Hum Pathol 2007, 38(August (8)):1207-1211. [Epub 2007 May 8].
13. Stephenson A.J., Scardino P.T., Kattan M.W., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007, 25(May (15)):2035-2041.
14. Boccon-Gibod L., Djavan W.B., Hammerer P., et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 2004, 58(April (4)):382-390.
15. King C.R., Spiotto M.T. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 2008, 71(May (1)):23-27. [Epub 2008 Jan 22].
16. Scattoni V., Roscigno M., Raber M., et al. Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 2003, 44(October (4)):407-414.
17. Kane C.J., Amling C.L., Johnstone P.A., Pak N., et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003, 61(March (3)):607-611.
18. Parsons K.F., Irani J., Fall M., et al. European Association of urology guidelines 2011.
19. Zeisel S.H. Dietary choline: biochemistry, physiology, and pharmacology. Annu Rev Nutr 1981, 1:95-121.
20. Ackerstaff E., Pflug B.R., Nelson J.B., Bhujwalla Z.M. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001, 61(May (9)):3599-3603.
21. Sutinen E., Nurmi M., Roivainen A., et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004, 31(March (3)):317-324. [Epub 2003 Nov 20].
22. Souvatzoglou M., Weirich G., Schwarzenboeck S., et al. The sensitivity of [11C]Choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res 2011, 17(June (11)):3751-3759. [Epub 2011 April 14].
23. McNeal J.E. The zonal anatomy of the prostate. Prostate 1981, 2(1):35-49.
24. Knopp M.V., Giesel F.L., Marcos H., von Tengg-Kobligk H., Choyke P. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Top Magn Reson Imaging 2001, 12(August (4)):301-308.
25. Somford D.M., Fütterer J.J., Hambrock T., Barentsz J.O. Diffusion and perfusion MR imaging of the prostate. Magn Reson Imaging Clin N Am 2008, 16(November (4)):685-695. ix.
26. Seitz M., Shukla-Dave A., Bjartell A., et al. Functional magnetic resonance imaging in prostate cancer. Eur Urol 2009, 55(April (4)):801-814. [Epub 2009 Jan 21].
27. Fuchsjäger M., Akin O., Shukla-Dave A., Pucar D., Hricak H. The role of MRI and MRSI in diagnosis, treatment selection, and post-treatment follow-up for prostate cancer. Clin Adv Hematol Oncol 2009, 7(March (3)):193-202.
28. Kirkham A.P., Emberton M., Allen C. How good is MRI at detecting and characterising cancer within the prostate?. Eur Urol 2006, 50(December (6)):1163-1174. discussion 1175 [Epub 2006 Jun 30].
29. Heinisch M., Dirisamer A., Loidl W., et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA<5ng/ml?. Mol Imaging Biol 2006, 8(January-February (1)):43-48.
30. Rinnab L., Mottaghy F.M., Blumstein N.M., et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007, 100(October (4)):786-793.
31. Vees H., Buchegger F., Albrecht S., et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1ng/mL) after radical prostatectomy. BJU Int 2007, 99(June (6)):1415-1420. [Epub 2007 Apr 8].
32. 11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008, 35(January (1)):9-17. [Epub 2007 Sep 9].
33. Rinnab L., Simon J., Hautmann R.E., et al. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol 2009, 27(October (5)):619-625. [Epub 2009 Feb 21].
34. Castellucci P., Fuccio C., Nanni C., et al. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009, 50(September (9)):1394-1400. [Epub 2009 Aug 18].
35. Giovacchini G., Picchio M., Scattoni V., et al. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010, 37(June (6)):1106-1116. [Epub 2010 Mar 20].
36. Giovacchini G., Picchio M., Briganti A., et al. [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol 2010, 184(September (3)):938-943.
37. Giovacchini G., Picchio M., Coradeschi E., et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010, 37(February (2)):301-309. [Epub 2009 Sep 15].
38. 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase<1.5ng/ml?. Eur J Nucl Med Mol Imaging 2011, 38(January (1)):55-63. [Epub 2010 Sep 17].
39. Picchio M., Briganti A., Fanti S., et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 2011, 59(January (1)):51-60. [Epub 2010 Sep 15].
40. Sella T., Schwartz L.H., Swindle P.W., et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004, 231(May (2)):379-385. [Epub 2004 Apr 2].
41. Casciani E., Polettini E., Carmenini E., et al. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol 2008, 190(May (5)):1187-1192.
42. Sciarra A., Panebianco V., Salciccia S., et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 2008, 54(September (3)):589-600. [Epub 2007 Dec 31].
43. Cirillo S., Petracchini M., Scotti L., et al. Endorectal magnetic resonance imaging at 1.5Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 2009, 19(March (3)):761-769. [Epub 2008 Sep 30].
44. Panebianco V., Sciarra A., Lisi D., et al. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol 2011, (February). [Epub ahead of print].
45. NCCN guidelines Version 4. 2011 Panel Members Prostate Cancer.
46. American Urological Association. Prostate cancer clinical guideline update panel members and consultants; 2007.
47. Heidenreich A., Bolla M., Jomiau S., et al. European Association of Urology guidelines on prostate cancer 2011.
48. Scattoni V., Picchio M., Suardi N., et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007, 52(August (2)):423-429. [Epub 2007 Mar 20].